Pages that link to "Q92024690"
Jump to navigation
Jump to search
The following pages link to Peter Irving (Q92024690):
Displaying 50 items.
- Probiotic effects on intestinal fermentation patterns in patients with irritable bowel syndrome (Q24655815) (← links)
- How should immunomodulators be optimized when used as combination therapy with anti-tumor necrosis factor agents in the management of inflammatory bowel disease? (Q26777409) (← links)
- Improving quality of care in inflammatory bowel disease: what changes can be made today? (Q26859105) (← links)
- Developing in vitro expanded CD45RA+ regulatory T cells as an adoptive cell therapy for Crohn's disease (Q28601365) (← links)
- Mechanisms and efficacy of dietary FODMAP restriction in IBS. (Q30738587) (← links)
- Manipulation of dietary short chain carbohydrates alters the pattern of gas production and genesis of symptoms in irritable bowel syndrome (Q33447288) (← links)
- Comparison of symptom response following advice for a diet low in fermentable carbohydrates (FODMAPs) versus standard dietary advice in patients with irritable bowel syndrome. (Q33450566) (← links)
- Fermentable carbohydrates (FODMAPs) exacerbate functional gastrointestinal symptoms in patients with inflammatory bowel disease: a randomised, double-blind, placebo-controlled, cross-over, re-challenge trial (Q33470528) (← links)
- Thioguanine in inflammatory bowel disease: Long-term efficacy and safety (Q33731976) (← links)
- Dietary poorly absorbed, short-chain carbohydrates increase delivery of water and fermentable substrates to the proximal colon (Q34094836) (← links)
- Reduction of dietary poorly absorbed short-chain carbohydrates (FODMAPs) improves abdominal symptoms in patients with inflammatory bowel disease-a pilot study. (Q34155802) (← links)
- Gluten causes gastrointestinal symptoms in subjects without celiac disease: a double-blind randomized placebo-controlled trial (Q34158501) (← links)
- Fermentable carbohydrate restriction reduces luminal bifidobacteria and gastrointestinal symptoms in patients with irritable bowel syndrome. (Q34284553) (← links)
- Inflammatory bowel disease in pregnancy: management strategy based on best evidence and European guidelines (Q34452571) (← links)
- Thiopurine withdrawal during sustained clinical remission in inflammatory bowel disease: relapse and recapture rates, with predictive factors in 237 patients (Q34516280) (← links)
- Comparison of the prevalence of fructose and lactose malabsorption across chronic intestinal disorders (Q34977681) (← links)
- Current Controversies in Crohn's Disease: A Roundtable Discussion of the BRIDGe Group (Q35013983) (← links)
- Cutting Edge: Regulator of G protein signaling-1 selectively regulates gut T cell trafficking and colitic potential (Q35195555) (← links)
- Percutaneous endoscopic gastrostomy with a jejunal port for severe hyperemesis gravidarum (Q35865600) (← links)
- Interleukin 6 Increases Production of Cytokines by Colonic Innate Lymphoid Cells in Mice and Patients With Chronic Intestinal Inflammation. (Q35964497) (← links)
- Thrombosis and inflammatory bowel disease (Q36277417) (← links)
- Relapse after withdrawal from anti-TNF therapy for inflammatory bowel disease: an observational study, plus systematic review and meta-analysis. (Q36692197) (← links)
- Review article: appropriate use of corticosteroids in Crohn's disease. (Q36884112) (← links)
- Drug interactions in inflammatory bowel disease. (Q37030998) (← links)
- Infections and IBD. (Q37050242) (← links)
- Management of distal ulcerative colitis: frequently asked questions analysis. (Q37091094) (← links)
- Epithelia Use Butyrophilin-like Molecules to Shape Organ-Specific γδ T Cell Compartments (Q37285138) (← links)
- Optimizing conventional therapies for inflammatory bowel disease (Q37630740) (← links)
- Recent advances in the management of inflammatory bowel disease. (Q37679873) (← links)
- Vedolizumab: toward a personalized therapy paradigm for people with ulcerative colitis. (Q37691599) (← links)
- Review article: malignancy on thiopurine treatment with special reference to inflammatory bowel disease (Q37735878) (← links)
- The appropriateness of concomitant immunomodulators with anti-tumor necrosis factor agents for Crohn's disease: one size does not fit all. (Q37745693) (← links)
- Optimization of conventional therapy in patients with IBD. (Q37942292) (← links)
- Setting priorities for comparative effectiveness research in inflammatory bowel disease: results of an international provider survey, expert RAND panel, and patient focus groups. (Q37984241) (← links)
- What changes in inflammatory bowel disease management can be implemented today? (Q37998607) (← links)
- Small bowel MR enterography: problem solving in Crohn's disease (Q38018561) (← links)
- Hair loss in patients with inflammatory bowel disease (Q38102564) (← links)
- Hidradenitis suppurativa: MRI features in anogenital disease. (Q38210154) (← links)
- Can we get more from our current treatments? (Q38218930) (← links)
- Are we using and monitoring thiopurines and biologics optimally? (Q38223561) (← links)
- Distinct management issues with Crohn's disease of the small intestine (Q38320897) (← links)
- Toxicity and response to thiopurines in patients with inflammatory bowel disease (Q38443981) (← links)
- Effects of Concomitant Immunomodulator Therapy on Efficacy and Safety of Anti-Tumor Necrosis Factor Therapy for Crohn's Disease: A Meta-analysis of Placebo-controlled Trials (Q38542682) (← links)
- Vedolizumab: early experience and medium-term outcomes from two UK tertiary IBD centres. (Q38608941) (← links)
- Utilisation of anti-TNF levels in a UK tertiary IBD centre. (Q38608944) (← links)
- Anti-TNF drug and antidrug antibody level monitoring in IBD: a practical guide (Q38608962) (← links)
- Reassessment of Crohn's disease treated with at least 12 months of anti-TNF therapy: how likely is treatment withdrawal? (Q38609023) (← links)
- Optimising use of thiopurines in inflammatory bowel disease (Q38662549) (← links)
- Long-term impact of the low-FODMAP diet on gastrointestinal symptoms, dietary intake, patient acceptability, and healthcare utilization in irritable bowel syndrome. (Q38679545) (← links)
- Diet Low in FODMAPs Reduces Symptoms in Patients With Irritable Bowel Syndrome and Probiotic Restores Bifidobacterium Species: A Randomized Controlled Trial. (Q38720349) (← links)